Abbreviated MRI for Liver Cancer Screening in Cirrhotic Patients, the FAST-MRI Study

Inclusion Criteria

• Liver cirrhosis of any etiology (diagnosed clinically and/or on blood tests and/or on Fibroscan and/or histologically and/or on cross-sectional imaging)
• It is permissible to include patients without prior negative imaging available as long as there is a clinical indication for HCC screening
• Both genders
• Age > 18 years
• Enrolled in screening/surveillance program for HCC
• Clinically indicated imaging-based screening for HCC
• Willing and able to complete all study procedures within specified time windows
• Ability to understand and the willingness to sign a written informed consent or similar
• Enrollment to other concurrent studies is permissible

Exclusion Criteria

• MRI contra-indications will follow local standard of care site policies used for clinical liver MRIs. At Icahn School of Medicine at Mount Sinai (ISMMS), these include metal implants, suspected or confirmed metal in eyes, cardiac pacemaker, implanted defibrillator, other implanted electronic devices, pregnancy, severe claustrophobia, acute kidney injury
• In patients with chronic renal failure with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2, the decision to inject gadoxetate will be based on local contrast policy
• Prior negative screening exam less than 5 months prior to enrollment
• Prior hepatic resection
• Post liver transplantation
• Previously treated HCC or other liver neoplasm
• Previously enrolled patients to this study
• Diagnosis of HCC prior to enrollment in study
• Any other condition or factor that in judgment of study investigator may interfere with study completion